technologynetworks

Pharmalink AB Gains Exclusive License to Archimedes Pharma’s TARGIT® Technology for Nefecon® (Pl-56) Program

Pharmalink AB has announced that it has gained an exclusive global license to Archimedes Pharma Ltd.’s TARGIT® drug delivery technology for use in its lead program, Nefecon® for the treatment of the ...
ascopubs.org

TARGIT-U.S.: A registry trial of targeted intraoperative radiation therapy following breast-conserving surgery.

A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2–, PIK3CA mutant or wild-type breast cancer. I-SPY 2 ...
Nature

New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer

The TARGIT-A trial reported risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy for breast cancer to be as effective as whole-breast external beam radiotherapy (EBRT).
PR Newswire

Pharmalink AB Gains Exclusive Licence to Archimedes Pharma's TARGIT® Technology for Nefecon® (PL-56) Program

Pharmalink AB, today announces it has gained an exclusive global license to Archimedes Pharma Ltd.'s TARGIT® drug delivery technology for use in its lead program, Nefecon® for the treatment of the ...